相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The role of dasatinib in the management of chronic myeloid leukemia
Runzhe Chen et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Transforming Growth Factor β Signaling Overcomes Dasatinib Resistance in Lung Cancer
Edna Gordian et al.
PLOS ONE (2014)
Rac1b negatively regulates TGF-beta 1-induced cell motility in pancreatic ductal epithelial cells by suppressing Smad signalling
Hendrik Ungefroren et al.
ONCOTARGET (2014)
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
David S. Hong et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
Cheng Ean Chee et al.
ONCOLOGIST (2013)
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells
Tobias Bartscht et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Concomitant Targeting of EGF Receptor, TGF-beta and Src Points to a Novel Therapeutic Approach in Pancreatic Cancer
Sophie Deharvengt et al.
PLOS ONE (2012)
Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
Juan Carlos Montero et al.
CLINICAL CANCER RESEARCH (2011)
Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth
Nagathihalli S. Nagaraj et al.
CLINICAL CANCER RESEARCH (2011)
The Src Family Kinase Inhibitors PP2 and PP1 Block TGF-Beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-Beta Receptors
H. Ungefroren et al.
CURRENT CANCER DRUG TARGETS (2011)
Dasatinib: An Anti-Tumour Agent via Src Inhibition
Antonio Gnoni et al.
CURRENT DRUG TARGETS (2011)
Differential roles of Src in transforming growth factor-β regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells
Hendrik Ungefroren et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2011)
Clonogenic Assay: Adherent Cells
Haloom Rafehi et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2011)
Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis
Jessica K. Gordon et al.
CURRENT OPINION IN RHEUMATOLOGY (2010)
Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Jennifer P. Morton et al.
GASTROENTEROLOGY (2010)
Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
Nagathihalli S. Nagaraj et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Jiannong Li et al.
NATURE CHEMICAL BIOLOGY (2010)
The Generation of Programmable Cells of Monocytic Origin Involves Partial Repression of Monocyte/Macrophage Markers and Reactivation of Pluripotency Genes
Hendrik Ungefroren et al.
STEM CELLS AND DEVELOPMENT (2010)
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
Q. Chang et al.
BRITISH JOURNAL OF CANCER (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Davide Melisi et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling
I. Ischenko et al.
ONCOGENE (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma:: Smad activation is crucial for both the tumor suppressive and prometastatic function
B. Schniewind et al.
ONCOGENE (2007)
Inhibition of transforming growth factor β signaling reduces pancreatic adenocarcinoma growth and invasiveness
Nicholas J. Gaspar et al.
MOLECULAR PHARMACOLOGY (2007)
Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion
Amy J. Galliher et al.
CANCER RESEARCH (2007)
Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
JG Trevino et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Clonogenic assay of cells in vitro
Nicolaas A. P. Franken et al.
NATURE PROTOCOLS (2006)
Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells
MS Duxbury et al.
CLINICAL CANCER RESEARCH (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Smad-dependent and Smad-independent pathways in TGF-β family signalling
R Derynck et al.
NATURE (2003)
Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness
H Ito et al.
SURGERY (2003)
Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity
DH Boschelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
分享论文
